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a b s t r a c t 
 
 
An analysis of the important intermolecular interactions of the active pharmaceutical ingredient lovastatin which contribute to 
the surface chemistry and attachment energy morphology is presented. The analysis is supported by a recent redetermination 
of the single-crystal structure (orthorhombic space group P212121) and targets the understanding and potential control of the 
morphology of lovastatin, which tends to crystallize in a needle-like morphology, where the aspect ratio varies depending on 
the nature of the solvent. The lattice energy was calculated to be 38.79 kcal mol 1 with a small contribution of 2.73 kcal mol 1 
from electrostatic interactions. The lattice structure is significantly stabilized by the hexahy-dronaphthalene ring of the 
molecule, which contributes 43.39% of the lattice energy. Synthon analysis shows that the dominant intermolecular interaction 
within the lattice structure of lovastatin is found to be along the a crystallographic axis, associated with a dispersive stacking 
interaction due to the close packing of 2 hexahydronaphthalene rings resulting in a total interaction energy of 6.46 kcal mol 1. 
The attachment energy morphology correlates well with the observed crystal morphology which exhibits a needle-like habit 
dominated by {0 1 1}, {0 2 0}, {0 0 2}, and {1 0 1} crystal forms. The needle capping faces are found to contain the short 
stacks of hexahydronaphthalene rings where the strong intermolecular synthon is found to contribute positively to the 
attachment energy and hence growth at this surface. This dominant intermolecular synthon is concluded to be the major cause 
of enhanced growth along the crystallographic a axis leading to the formation of a needle-like morphology. A habit 
modification strategy is discussed which uses recrystallization from apolar solvents to reduce the effective growth rate at the 
needle-capping sur-faces. This is supported through experimental data which shows that crystals obtained from crystallization 
in hexane and methyl-cyclohexane have significantly reduced aspect ratios in comparison to those grown from the more polar 
methanol and ethyl acetate solutions. Crystals obtained from nitromethane solutions were also found to have a very large 
reduction in aspect ratio to a prismatic morphology reflecting this solvent's propensity to interact with hydrophobic surfaces, 
critically with no polymorph change. 
 
 
 
 
 
 
 
Introduction 
 
Mevinolinic acid or lovastatin belongs to the statin class of drug 
compounds, one of the most widely prescribed drug classes worldwide for the 
treatment of hypercholesterolemia. Lovastatin targets and inhibits the enzyme 
hydroxymethylglutaryl coenzyme A reductase, which plays a key role in 
initiating the synthesis of 
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cholesterol; hence, lovastatin hinders the biosynthesis pathway of cholesterol. 
Lovastatin is generally isolated through a chemical synthesis or biosynthesis 
fermentation route, where the product is then isolated and purified through a 
recrystallization strategy, generally from alcohol or acetone/water mixes.1 
 
Lovastatin has been the target of many physicochemical screening studies 
within the literature due to its importance as an industrial active 
pharmaceutical ingredient (API). The solid-state physicochemical properties 
of lovastatin have been studied using thermal analysis methods; the melting 
point was found to be 445 K and where the crystalline material undergoes 
amorphization when recrystallized with the preservative 
butylhydroxyanisole.2 The sol-ubility of lovastatin was measured in a number 
of solvent systems, namely in a series of homologous acetates,3 alcohols,4 
and also in 
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acetone/water mixtures,5 where the solubility is lower in polar solvents due to 
the hydrophobic nature of the compound. Addi-tionally, the nucleation 
kinetics of lovastatin have been determined using turbidometric techniques in 
ethanol, methanol, and acetone solutions, where the mechanism of nucleation 
was found to be instantaneous in ethanol and acetone and progressive in 
methanol.4 
 
Due to the hydrophobicity of lovastatin, the drug falls into the second 
class of drug compounds under the Biopharmaceutics Classification 
System,6,7 where the drug exhibits high permeability and low solubility, the 
molecular structure and material descriptors for lovastatin are provided in S1 
of the Supplementary Information. As a result, the drug is impacted by poor 
bioavailability and hence efforts to improve the absorption of the drug have 
included nanoparticle synthesis and implementation of lipid-based carrier 
systems.8,9 Lovastatin also exhibits a needle-like morphology when 
recrystallized from solution, which can lead to problematic downstream 
processing issues such as poor particle flow, prob-lematic filtration, and 
particle breakage.10 
 
The physicochemical and mechanical properties of crystalline materials 
can be calculated using molecular modeling tools through atom-atom 
summation methods which use atomistic forcefields to calculate 
intermolecular interaction strength and directionality.11-17 Much progress has 
been made in this field, particularly when applying these “synthonic 
engineering” methodologies to organic molecular crystals,18,19 where particle 
morphology,20,21 solvent-surface interactions,22 surface chemistry23 and 
excipient-API in-teractions24 are some of the emerging areas of interest. 
Nguyen25 et al recently applied a synthonic engineering approach to under-
stand the interfacial stability of the crystallographic faces of ibuprofen and 
rationalize the various aspect ratio crystals obtained from differing solution 
environments during crystal growth. Ros-bottom26 et al have also used 
synthonic engineering by applying a grid-based surface searching 
methodology27-29 to explain the anisotropic wettability of the crystal surfaces 
of ibuprofen. 
 
This article aims at using the approaches of synthonic engineering and 
molecular modeling discussed above to further understand the bulk crystal 
chemistry and surface chemistry 
 
of lovastatin in relation to its observed needle-like morphology. Additionally, 
it aims at quantifying the extrinsic (surface-termi-nated) synthon contribution 
to the attachment of molecules at the growing crystal surfaces. This is part of 
an overall strategy to effect the habit modification of this material to mitigate 
the impact of the observed needle-like morphology of lovastatin by providing 
a fundamental molecular understanding of both the crystallographic structure 
and the nature of the interactions of the solute with its surrounding solution 
environment. 
 
 
Materials and Methods 
 
Chemicals 
 
Lovastatin was used as supplied by the EPSRC Future Continuous 
Manufacturing and Advanced Crystallisation Research Hub and originally 
purchased through Molekula. Ethyl acetate HPLC >99.95%, methanol HPLC 
99.61%, and hexane HPLC 99.9% purity were used as supplied by Fisher. 
Toluene reagent grade >99.7% and methyl cyclohexane anhydrous >99% 
were used as supplied by Sigma-Aldrich. 
 
 
Experimental Methodology 
 
Single-Crystal X-Ray Diffraction 
 
Single crystals of lovastatin (colorless needles) were obtained by slow 
evaporation from saturated ethyl acetate, methanol, methyl cyclohexane, 
toluene, hexane, and nitromethane solutions at 25 C. Single-crystal X-ray 
diffraction data were recorded at the University of Bath, on a dual-source 
Rigaku Oxford Diffraction Gemini A Ultra diffractometer, equipped with an 
Atlas CCD detector and an Oxford Cryosystems Cryojet-XL liquid nitrogen 
flow device for tempera-ture control. Data collection, indexing, and 
integration procedures were performed using the Rigaku Oxford Diffraction 
software CrysAlis Pro.30 Using Olex2,31 the structure was solved by dual-
space methods using ShelXT32 and refined by least squares methods using 
ShelXL.33 Hydrogen atoms were positioned geometrically and refined using a 
riding model. The hydrogen atom isotropic displacement parameters were 
fixed to Uiso (H) ¼ 1.5 (for CH3) or Uiso (H) ¼ 1.2 (for CH2 and CH) the 
Ueq of the parent atom. The structure is included in the Cambridge Structural 
Data-base as a CSD Communication with CSD refcode CEKBEZ01.34 
 
 
Powder X-Ray Diffraction 
 
Powder X-ray diffraction was used for polymorph characteriza-tion of the 
prepared lovastatin crystals from slow solvent evapora-tion. The powder 
samples were ground to a powder using a mortar and pestle then mounted on 
a single-cut silicon crystal powder holder and scanned using a Bruker35 D8 
advanced X-ray diffrac-tometer using Cu Ka radiation and a germanium 
primary mono-chromator in Bragg-Brentano reflection geometry. The step 
size was 0.033 2q with a step time of 0.7 s/step over a 2q range of 2-39.8 2q. 
The detector used was a Vantec-1 position-sensitive detector. 
 
 
Modeling Methodology 
 
Visualization of the crystal structure was carried out using the Cambridge 
Crystallographic Data Centre’s Mercury software.36 The conformational 
analysis of lovastatin (CEKBEZ01)34 was performed using the Forcite 
module in Accelrys Materials Studio37 where the geometry of a single 
lovastatin molecule of the major disorder component was optimized with 
respect to the potential energy surface to minimize the total energy of the 
structure. The PCFF38-40 forcefield was used and the atomic charges were 
calculated using Gasteiger41,42; the energy convergence was calculated using 
the SMART algorithm. The geometry of this gas phaseeoptimized 
    
molecule of lovastatin was then compared to the conformation of was freely refined using standard PART32 instructions to determine 
the molecule in the crystal structure.  a ratio of 57% of the major component and 43% of the minor 
The lattice, slice, and attachment energies were calculated using component  (see  Supplementary  Information,  S2  Fig.  3).  The 
an atom-atom summation method using Habit9812,13  using the conformation of the major component overlays well with the re- 
Momany43 potential where the atomistic charges were calculated ported  room  temperature  arrangement  for  this  group  (see 
within Mopac.44 Habit98 builds a series of unit cells which expand Supplementary Information, S2 Fig. 2). Although no disorder was 
outward from a central unit cell; the intermolecular interaction reported by Sato et al., analysis of their original structure data does 
between a central molecule and all others within an expanding show that the anisotropic displacement parameters for the S- 
sphere, the radius of which was set as 1-30 Å to ensure lattice energy butanoate chain are significantly larger than for the rest of the 
convergence, is calculated. The resulting lattice energy was parti- structure (e.g., the reported anisotropic displacement parameter for 
tioned into the slice and attachment energy based on Equation 1.45 the carbon atom of the terminal CH3 group is ca. 2 larger than that 
Ecr 
¼
 Esl 
þ
 Eatt (1) 
of other CH3 groups in the structure).52 These observations indicate 
that the presence of disorder cannot be entirely ruled out in the 
    room temperature structure and are thus consistent with our own 
ε
hkl 
¼ Esl 
(2) 
observations at low temperature. It should also be noted that the 
Ecr 
 
data quality is also remarkably improved in the 150 K redetermi- 
where Ecr is the lattice energy, Esl is the slice energy, and Eatt is the 
nation, with a residual factor R1 ¼ 3.17% in comparison to R1 ¼ 8.2% 
for the original dataset. A reduction in data quality at room tem- 
attachment  energy.  The  important  morphological  faces  were perature is common54 and hence may reasonably have prevented 
selected based upon the Bravais, Friedel, Donnay, and Harker fi  
(BFDH) rule46-48  which states the surfaces with lowest surface 
reliable re nement of any potential disorder in the structure 
collected in 1984. Given this comparison, we chose the 150 K 
energy will be those with the greatest interplanar d-spacing and redetermination as the basis for our molecular modeling calcula- 
were chosen using the Morphology tool with Materials Studio. The tions which were performed using the major component, however 
predicted morphology was calculated using the top 10 crystal for  clarity  the  methodology  was  repeated  using  the  minor 
planes sorted by the highest d-spacing where the attachment en- component where the data are comparable and the conclusions 
ergy of those faces was calculated and the attachment energy was drawn from this analysis are in agreement; this is provided in S3 of 
approximated to a surface-specific growth rate. The morphology the Supplementary Information. 
 
was then reconstructed using a Wulff plot using SHAPE.36,49 The Figure 1a provides a view of the lovastatin crystal structure 
surface anisotropy factors,50,51 εhkl, which describe the termination down the b axis which highlights the close-packed nature of the 
of the synthons at a specific habit face, were calculated using hexahydronaphthalene rings which run down the short a axis of 
Equation 2 and expressed as a percentage. The plane rugosity of the the crystal structure. The crystal structure contains 1 hydrogen 
crystal faces was calculated based on the average root mean square bond between the alcohol functionality and the carbonyl of the S- 
displacement of the atomic centers of the molecules in the unit cell butanoate ester group. These interactions form a broken chain 
along the growth normal within the d-spacing of the crystallo- which runs ~30  from plane normal down the crystallographic b 
graphic planes. The plane rugosity provides a simple measure of the axis. Additionally, there is a notable short contact between the 
variation in height for a given crystallographic plane and hence carbonyl group of the tetrahydropyran ring and an acidic proton on 
provides a description of the smoothness for a given crystal plane at an adjacent tetrahydropyran ring which runs ~20  from plane 
an atomic level. The intermolecular synthons were analyzed and normal to the crystallographic a axis; an enlarged view of this 
ranked by their total intermolecular energy contribution to the contact is provided in S4 of the Supplementary Information. 
overall lattice energy of lovastatin following a methodology pre- 
  
viously reported by Rosbottom et al.17  Conformational Analysis  
 
Results 
 
Single-crystal Structure Determination 
 
The single-crystal structure of lovastatin (CSD refcode CEKBEZ) was 
first published by Sato et al.52 in 1984 and was determined from room 
temperature X-ray diffraction data. The data presented in this article are a 
modern redetermination of the structure at low temperature (150 K), 
confirming that the overall structure of lovastatin remains largely unchanged 
on cooling, and the crystal structure refinement data of lovastatin are provided 
in S2 of the Supplementary Information. No structural phase transition is 
observed on cooling, with the same P212121 space group retained at 150 K 
and slightly reduced unit cell parameters, as is in keeping with thermal 
contraction on cooling (overall decrease in unit cell volume ¼ ca. 2%). An 
overlay of the 2 structures in the CSD software Mercury53 confirms that the 
molecular conformation is largely unchanged on cooling, with a root mean 
square deviation of 0.0214 calculated between the 2 structures (see 
Supplementary Information, S2 Fig. 2). The key difference between the new 
structure and that published by Sato et al. is that disorder in the S-butanoate 
ester group was resolved at low temperature. The S-butanoate group is found 
to be disordered over 2 positions and 
 
The calculated gas phase conformation of a lovastatin molecule is shown 
as yellow in Figure 2 and is overlaid for comparison to the conformation of 
the molecule in the asymmetric unit found in the crystal structure, colored by 
atom type in Figure 2. The data shows that in general the conformation of the 
lovastatin molecule does not change dramatically when going from the gas 
phase to the crystal structure. This is particularly observable in the conforma-
tions of the hexahydronaphthalene and the S-butanoate ester groups, which 
exhibit very little conformational change. The tor-sion around the carbon 
backbone highlighted as red T1 in view A, Figure 2 highlights this small 
change which only differs by ~1 , 
 
172 -171 when going from the gas phase to the crystalline phase. The 
tetrahydropyran ring group, however, does undergo some conformational 
rotation when going from the gas phase to the solid phase, where the ring is 
rotated ~23 , 154 -177 , through torsion T2 highlighted in green in view B, 
Figure 2. The total energy of the 
molecule within the crystal structure was found to be 19.70 kcal 
mol 1 and the optimized gas phase molecule had a total energy 
 
of 20.82 kcal mol 1, which correlates well with a small confor-mational 
change. Overall, this analysis is consistent with the ma-terial only having a 
single known polymorph, where the crystal structure conformation is already 
relatively close to the molecular free energy minima. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The crystal structure of lovastatin viewed down the a and c axes. 
 
 
Lattice Energy and Intermolecular Synthon Analysis 
 
The lattice energy of lovastatin converged at 38.79 kcal mol 1 
where the electrostatic contribution converges at 2.73 kcal mol 1 
 
at a maximum convergence distance of 30 Å. The lattice energy and 
electrostatic contribution energy as a function of limiting radius are provided 
in Figure 3a, and this shows that the lattice energy con-verges in 2 shells, the 
first at 6-9 Å and the second at 13 Å as shown in Figure 3b. The very low 
contribution to the lattice energy pro-vided by electrostatic interactions is 
unsurprising considering the largely dispersive nature of the lovastatin 
molecule. 
 
The lattice energy of lovastatin was further collapsed onto the asymmetric 
molecular unit to provide a quantitative analysis of the relative functional 
group contribution to stabilizing the crystal lattice. Figure 4a provides this 
quantitative breakdown onto the lovastatin molecule where the 
hexahydronaphthalene group (a) contributes 43.39% of the lattice energy, 
indicating the importance of dispersive interactions within the lovastatin 
lattice structure. The tetrahydropyran functionality (b) contributes 29.42% 
and the S-butanoate ester group (g) contributes 27.24%; interestingly, the b 
group contains the acidic proton short contact between the carbonyl group of 
the tetrahydropyran ring and the protons of an adjacent tetrahydropyran ring. 
Whereas the g group contains the long-range H-bond (~2.0 Å) from the ester 
functionality, this highlights the subtle differences between the H-bonding 
compo-nent and the short contact component to the lattice energy where the 
acidic proton short contact seems to play a greater role in contributing to the 
stabilization of the lattice structure. 
 
 
Figure 4b summarizes the top 7 intermolecular synthons, ranked by 
intermolecular interaction energy, which contribute to the lattice energy of 
lovastatin, additionally Table 1 summarizes the breakdown of these synthonic 
interactions into attractive, repul-sive, coulombic, and total energy from the 
forcefield calculation. Synthon A provides the largest contribution to the 
lattice energy of lovastatin, 6.46 kcal/mol and 33.31% of the total lattice 
energy, ~ 3.5 kcal/mol greater than synthon B which highlights the impor-
tance of this close-packed interaction which is ~98% dominated by dispersive 
interactions between the hexahydronaphthalene groups as summarized in 
Table 1. Synthons B and E contain a larger coulombic component, ~20% and 
26% contribution to the overall interaction, respectively. This is due to the 
hydrogen bond between 
 
 
the alcohol proton and carbonyl oxygen in synthon B and the acidic proton 
short contact in synthon E as shown in Figure 4b. Synthons F and G provide a 
relatively small contribution to the overall crystal lattice energy with weak 
dispersive-type interactions of 1.05 and 0.92 kcal/mol, respectively. These 7 
synthons provide 93.06% of the total lattice energy of lovastatin and hence 
analysis of further intermolecular synthons was not carried out due to their 
low contribution to the overall lattice energy. 
 
The strongest intermolecular synthon, Synthon A, comprises of a close-
stacked interaction of the hexahydronaphthalene rings. Figure 4b provides a 
schematic of Synthon A with the breakdown of the interaction energy onto 
the functional groups of lovastatin. This shows that the hexahydronaphthalene 
rings provide 54.66% of the interaction energy and the b and g functional 
groups provide 23.40% and 21.52%, respectively. Further to this, it was found 
that the components of this intermolecular interaction energy are dispersive in 
nature as highlighted by the breakdown of the energy into dispersive and 
coulombic components as highlighted in Table 1. 
 
 
Attachment Energy Morphology and Surface Chemistry 
 
The attachment energy morphology of lovastatin is provided in Figure 5 
where the simulation yields a needle-like morphology 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Conformational overlay of the gas phaseeoptimized lovastatin molecule and the 
molecule in the asymmetric unit of lovastatin. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Convergence of the calculated lattice total energy and the % contribution to the lattice energy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. (a) The percentage contribution to the lattice energy provided by the 3 functional groups of the lovastatin asymmetric unit and the top 7 intermolecular synthons which contribute to the 
lattice energy of lovastatin. 
  
Table 1 
 
The Top 7 Intermolecular Synthons Which Contribute to the Lattice Energy of Lovastatin, Ranked in Order of Total Interaction Energy; Also Provided Is the Contribution of Each Synthon to the 
Total Lattice Energy and Also the Contributions in Multiplicity of Synthons to the Surfaces Present in the Attachment Energy Morphology 
 
 
Synthon aDistance/Å Dispersive Coulombic Total % Contribution Contribution to {0 1 1} Contribution to {0 2 0} Contribution to {1 0 1} 
  Total (kcal mol 1) (kcal mol 1) of Lattice Attachment Energy Attachment Energy Attachment Energy 
  (kcal mol 1)  Energy Contribution Contribution Contribution 
A 5.89 6.31 0.16 6.46 33.31 0 0 4 
B 11.11 2.47 0.50 2.98 15.36 2 4 3 
C 10.35 2.58 0.02 2.56 13.20 2 4 1 
D 10.03 2.04 0.08 2.12 10.93 2 4 2 
E 11.39 1.45 0.51 1.96 10.11 2 4 2 
F 11.11 0.92 0.13 1.05 5.41 2 0 2 
G 11.91 0.90 0.01 0.92 4.74 2 0 2 
     Total ¼ 93.06%    
 
a
 Distance is calculated from the center of gravity of the 2 molecules contributing to the intermolecular interaction. 
 
dominated by {0 1 1}, {0 2 0}, {1 0 1}, and {0 0 2} surfaces, where the {1 0 
1} surfaces are the needle capping faces. The calculated attachment energy 
morphology is in reasonably good agreement with micrographs of lovastatin 
crystals grown from ethyl acetate and toluene solutions, shown in Figure 6 
which present as needle-like crystallites albeit of a higher aspect ratio in 
comparison to the model morphology, a more detailed figure of the calculated 
attachment energy morphology is provided in S5 in the Supplementary 
Information. 
 
Table 2 summarizes the slice, attachment energy, and % surface saturation 
of the top 10 BFDH face list of lovastatin, where the 
 
 
highlighted faces are those which are present in the calculated attachment 
energy morphology. Interestingly, the % surface satu-ration of the 
morphologically important surfaces correlates well to the morphology, 
whereby the needle capping surfaces, {1 0 1}, have by far the lowest surface 
saturation, 30.21%, meaning growth in this direction would be favored due to 
unsatisfied surface-active inter-molecular interactions. Conversely, the slow-
growing {0 1 1} sur-face has the highest surface saturation, 66.69%, meaning 
growth is likely to be slower in this direction. 
 
The overall contribution of the top 5 intermolecular synthons, presented in 
Figure 4, to the attachment energy of the {0 11}, {0 2 0}, 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Attachment energy morphology of lovastatin together with the surface chemistry of the habit planes. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Micrographs of lovastatin crystals grown by slow solvent evaporation. 
 
 
and {1 0 1} surfaces was calculated to assess the relative importance to the 
growth of these faces. This analysis is summarized in Table 1 where the 
multiplicity of each synthon is presented. This analysis shows that, 
interestingly, the needle capping {1 0 1} surface is the only morphological 
surface to contain Synthon A as an extrinsic growth synthon. This correlates 
well with the observation that the morphology is extended down the a axis 
through this surface. Conversely, the larger, slower-growing {0 1 1} surface 
has no contribution from Synthon A to its attachment energy and only has the 
lower-energy synthons B, C, D, and E with a multiplicity of 2, as extrinsic 
synthons. 
 
A visualization of the surface chemistry for the {0 11}, {0 2 0}, and {10 
1} surfaces of lovastatin is provided in Figure 5. This indicates the close-
packed nature of the {1 0 1} needle capping surface and shows the relative 
availability of the hexahydronaphthalene rings at the 
 
 
surface which can provide stacking interactions to form the energetically 
favorable Synthon A, which was highlighted in the previous analysis, and 
contributes to the attachment energy at this surface. Additionally, the 
calculated plane rugosity (Table 2) of the {1 0 1} surface was found to be 
2.61 Å which is low relative to the {0 1 1} and {0 2 0} surfaces. This could 
provide a more favorable growth environment, whereby desolvation of the 
surface followed by solute integration is to some extent less rate limited by 
the desolvation step due to solvent trapping at the surface for example. 
Conversely, the {0 1 1} and {0 2 0} surfaces have significantly higher 
calculated plane rugosity than the needle capping surface, which could impact 
desolvation, where the channels trap solvent and hence decrease the rate of 
desolvation and effectively decrease the growth rate at these surfaces relative 
to the needle capping surface. 
  
Table 2 
 
The Calculated Slice and Attachment Energies Together With the % Surface Saturation of the Top 10 BFDH Face List for Lovastatin, the Major Surfaces Which Appear in the Calculated Attachment 
Energy Morphology 
 
 
Surface d-Spacing/Å Plane Rugosity/Å Slice Energy/Kcal mol 1 Attachment Energy/Kcal mol 1 % Surface Saturation 
{011} 13.61 7.22 ¡25.87 ¡12.91 66.69 
{020} 8.66 5.88 ¡17.43 ¡21.35 44.93 
{101} 5.69 2.61 ¡11.72 ¡27.06 30.21 
{002} 10.99 6.09 25.3 13.48 65.22 
{012} 9.28 7.26 23.75 15.04 61.23 
{021} 8.06 6.69 20.59 18.2 53.08 
{013} 6.75 7.08 23.71 15.07 61.12 
{031} 5.59 6.44 15.38 23.41 39.65 
{023} 5.6 7.34 23.71 15.07 61.12 
{110} 5.6 3.41 11.83 26.95 30.50 
      
 
 
Bold font indicates surfaces which appear in the calculated attachment energy morphology model. 
 
 
Synthonic and Surface Chemistry Analysis in Relation to the Needle 
Morphology of Lovastatin 
 
This analysis has indicated the importance of Synthon A, not only in 
contributing to the stabilization of the lattice structure of lovastatin but also in 
contributing to the attachment energy as an extrinsic synthon on the needle 
capping {1 0 1} surface. The com-bination of a highly favorable dispersive 
stacking interaction be-tween the 2 hexahydronaphthalene groups, the low 
calculated {1 0 1} plane rugosity, and the availability of the hexahydronaph-
thalene groups at the capping surface are the likely cause of the formation of a 
needle-like morphology due to faster crystal growth along the 
crystallographic a axis of lovastatin. 
 
The identification of Synthon A, not only as an important possible growth 
synthon but also as an extrinsic synthon at the needle capping face, leads to 
the postulation of a crystallization strategy to hinder or at least reduce the 
aspect ratio of the crystals through selective binding of the 
hexahydronaphthalene rings to hinder formation of Synthon A. Micrographs 
of lovastatin crystals obtained from slow solvent evaporation in some 
nonpolar solvents are provided in Figure 6. This highlights that in methyl 
cyclohexane, toluene, hexane, and nitromethane solutions, the crystallites 
recovered had a significantly lower aspect ratio when compared to those 
grown in polar protic or polar aprotic solvents such as methanol and ethyl 
acetate. This is likely due to selectively binding of the apolar component of 
the lovastatin molecule which would effectively decrease the desolvation rate 
of the molecule at the hexahydronaphthalene group in the solution state, 
hindering the formation of Synthon A and also decrease the desolvation rate 
of the {1 0 1} capping face relative to the side and top faces. This reduction in 
relative growth rate would likely decrease the aspect ratio to a more equant 
morphology. 
 
 
Nitromethane provides an interesting result as this solvent considerably 
reduces the aspect ratio of the lovastatin crystals to a prismatic-like 
morphology. The crystals obtained were analyzed for polymorph changes, 
where powder X-ray diffraction showed the crystals to be of the same crystal 
structure and hence no polymorph change or solvate formation had taken 
place, these data are pro-vided in S6 of the Supplementary Information. The 
cause of this dramatic reduction in needle-like morphology is likely to be the 
prevention of Synthon A formation and the reduction in the growth rate on the 
needle capping face. This dramatic habit modification has also been shown for 
the case of p-aminobenzoic acid, where the needle-like alpha form can be 
reduced to a significantly more prismatic crystal habit through 
recrystallization from nitromethane solutions. This was found to be caused by 
interaction of nitro-methane with the benzene rings of p-aminobenzoic acid 
and hence disrupting strong p-p stacking interactions which cause the needle-
like morphology in the material. This is also likely the case for 
 
 
lovastatin, where the nitromethane could preferentially bind to the 
hexahydronaphthalene ring system, probably through the unsat-urated carbon 
atoms, and hence prevent Synthon A formation. 
 
The effect of “blocking” Synthon A using solvation could also be similarly 
achieved through additive addition using the same prin-ciple. Additives such 
as polyaromatic or polycyclic hydrocarbons, for example, naphthalene, could 
have the same effect by blocking Synthon A and also through disruption of 
the molecular recognition at the {1 0 1} capping surface, reducing the 
effective growth rate. 
 
Conclusions 
 
A molecular modeling analysis of the intrinsic and extrinsic synthons of 
the API lovastatin in relation to its bulk and surface properties has been 
presented to rationalize the materials’ observed needle-like morphology. The 
synthonic analysis revealed a strong intermolecular interaction in the bulk 
structure which consisted of a close-packed stacking interaction of 2 hexahy-
dronaphthalene rings. This intermolecular interaction was found to be ~3.5 
kcal mol 1 more energetically favorable than the second strongest synthonic 
interaction in the bulk structure. Additionally, the hexahydronaphthalene ring 
of lovastatin was found to contribute 43.39% of the calculated lattice energy 
of the material, where 99.83% of this was found to be of a dispersive nature. 
 
 
The calculated attachment energy morphological model corre-lated 
reasonably well with the experimental morphology observed for crystals 
grown from ethyl acetate solutions and was dominated by {0 1 1}, {0 2 0}, {1 
0 1}, and {0 0 2} surfaces. Analysis of the surface chemistry of the habit 
faces revealed that the {1 0 1} needle capping face was highly undersaturated 
with respect to its extrinsic synthons, where the surface saturation was 
calculated as 30.21%, compared to 66.69% and 44.93% for the slower 
growing {0 1 1} and the {0 2 0} surfaces, respectively. The {1 0 1} needle 
capping face also was found to have a lower plane rugosity, 2.61 Å, compared 
to 5.88 Å and 7.22 Å for the {0 2 0} and {0 1 1} faces, respectively. The 
analysis of the surface chemistry revealed that critically, Synthon A 
contributes positively to the attachment energy of the {1 0 1} capping surface 
and does not contribute to the attachment energy of either the {0 2 0} or {0 1 
1} faces. Hence, it was concluded that Synthon A is the major cause for the 
formation of a needle-like morphology in lovastatin down the crystallographic 
a axis and a recrystallization strategy using aprotic or apolar solvents or addi-
tives could be used as habit modifiers for this material to reduce the aspect 
ratio of the crystals. 
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